Enlivex Therapeutics (ENLV) Competitors $1.24 +0.06 (+5.08%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ENLV vs. SKYE, PYXS, IPSC, CLLS, TNXP, ORMP, SCLX, GNTA, MIST, and TLSAShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Skye Bioscience (SKYE), Pyxis Oncology (PYXS), Century Therapeutics (IPSC), Cellectis (CLLS), Tonix Pharmaceuticals (TNXP), Oramed Pharmaceuticals (ORMP), Scilex (SCLX), Genenta Science (GNTA), Milestone Pharmaceuticals (MIST), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Skye Bioscience Pyxis Oncology Century Therapeutics Cellectis Tonix Pharmaceuticals Oramed Pharmaceuticals Scilex Genenta Science Milestone Pharmaceuticals Tiziana Life Sciences Enlivex Therapeutics (NASDAQ:ENLV) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking. Do analysts rate ENLV or SKYE? Enlivex Therapeutics currently has a consensus target price of $9.50, indicating a potential upside of 666.13%. Skye Bioscience has a consensus target price of $18.67, indicating a potential upside of 591.36%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Skye Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, ENLV or SKYE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$29.07M-$0.98-1.27Skye BioscienceN/AN/A-$37.65MN/AN/A Do institutionals & insiders have more ownership in ENLV or SKYE? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 3.0% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is ENLV or SKYE more profitable? Skye Bioscience's return on equity of -45.78% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -67.57% -58.45% Skye Bioscience N/A -45.78%-37.44% Does the media refer more to ENLV or SKYE? In the previous week, Skye Bioscience had 5 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 5 mentions for Skye Bioscience and 0 mentions for Enlivex Therapeutics. Skye Bioscience's average media sentiment score of 0.54 beat Enlivex Therapeutics' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media. Company Overall Sentiment Enlivex Therapeutics Neutral Skye Bioscience Positive Which has more volatility & risk, ENLV or SKYE? Enlivex Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500. Does the MarketBeat Community favor ENLV or SKYE? Enlivex Therapeutics received 44 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 79.71% of users gave Enlivex Therapeutics an outperform vote. CompanyUnderperformOutperformEnlivex TherapeuticsOutperform Votes5579.71% Underperform Votes1420.29% Skye BioscienceOutperform Votes11100.00% Underperform VotesNo Votes SummarySkye Bioscience beats Enlivex Therapeutics on 8 of the 14 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.54M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-1.2710.5991.3417.19Price / SalesN/A195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book0.775.104.794.78Net Income-$29.07M$151.51M$120.07M$225.60M7 Day Performance3.33%-2.15%-1.90%-1.23%1 Month Performance43.77%-3.14%11.45%3.37%1 Year Performance-45.61%11.50%30.63%16.58% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics2.3234 of 5 stars$1.24+5.1%$9.50+666.1%-36.6%$26.54MN/A-1.2770SKYESkye Bioscience2.1885 of 5 stars$3.28-3.0%$18.67+469.1%-10.6%$99.51MN/A0.0011News CoveragePositive NewsPYXSPyxis Oncology2.1442 of 5 stars$1.67+3.1%$10.00+498.8%-2.9%$99.32MN/A-1.5760Analyst ForecastNews CoveragePositive NewsIPSCCentury Therapeutics1.8231 of 5 stars$1.17-4.5%$11.60+895.7%-52.6%$99.06M$2.68M-0.66170High Trading VolumeCLLSCellectis3.1721 of 5 stars$1.76-0.2%$7.00+298.6%-53.8%$97.62M$9.19M-1.35290TNXPTonix Pharmaceuticals3.6175 of 5 stars$0.52+117.0%$53.50+10,149.0%-95.0%$97.56M$11.29M0.00103High Trading VolumeORMPOramed Pharmaceuticals1.6807 of 5 stars$2.42-2.0%N/A+8.2%$97.55M$1.34M22.4510Analyst UpgradePositive NewsSCLXScilex3.1746 of 5 stars$0.51+0.2%$11.33+2,128.8%-65.6%$97.53M$46.74M-0.3580GNTAGenenta Science2.961 of 5 stars$5.30+3.3%$25.00+371.7%+0.2%$96.94MN/A0.007News CoverageGap UpMISTMilestone Pharmaceuticals1.6394 of 5 stars$1.80flat$12.00+566.7%-34.8%$95.99M$1M-2.2230Positive NewsTLSATiziana Life Sciences1.2031 of 5 stars$0.91-3.5%N/A+30.8%$95.76MN/A0.008Gap Down Related Companies and Tools Related Companies SKYE Competitors PYXS Competitors IPSC Competitors CLLS Competitors TNXP Competitors ORMP Competitors SCLX Competitors GNTA Competitors MIST Competitors TLSA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENLV) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENLV Stock Alerts